Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 1.00 |
| ▸ | CTSL | P07711 | 2/20 | 0.56 |
| ▸ | CTSS | P25774 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 6/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 4/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.46 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | MMP14 | P50281 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.43 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16450211 | 0.79 | PIN1 (0.68) | PIN1LPAR1LPAR3 | |
| SCHEMBL18406927 | 0.77 | CTSL (0.64) | PIN1CTSLCTSSMMP2CA2 | |
| SCHEMBL18406917 | 0.77 | CTSL (0.64) | PIN1CTSLCTSSMMP2CA2 | |
| SCHEMBL8532716 | 0.75 | PIN1 (0.59) | PIN1CTSLCTSSMMP2CA9 | |
| SCHEMBL6326006 | 0.75 | PIN1 (1.00) | PIN1CTSLLPAR1LPAR3 | |
| SCHEMBL6269412 | 0.75 | PIN1 (0.75) | PIN1LPAR1LPAR3 | |
| SCHEMBL7325853 | 0.74 | CA2 (0.67) | PIN1CTSLMMP2CA12CA9 | |
| SCHEMBL18405738 | 0.74 | CTSL (0.59) | PIN1CTSLCTSSMMP2CA2 | |
| SCHEMBL10779170 | 0.73 | CA2 (0.65) | PIN1CTSLMMP2CA12CA9 | |
| SCHEMBL10779164 | 0.73 | CA2 (0.65) | PIN1CTSLMMP2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603926-A1 | PHOSPHATE/SULFATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN INTERACTING NIMA (PIN1) | PFIZER INC. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050250742-A1 | Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting NIMA (PIN1) | PFIZER INC. | 2005-11-10 | — | — | US | disclosed |
| WO-2004087720-A1 | PHOSPHATE/SULFATE ESTER COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN INTERACTING NIMA (PIN1) | PFIZER INC. (US) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250742-A1 | Phosphate/sulfate ester compounds and pharmaceutical composition for inhibiting protein interacting NIMA (PIN1) | PIN1, PSTPIP2, NIM1K | PIN1 1/4885CTSL 3952/4885CTSS 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.